GEO DataSets

(Submitter supplied) Proteomic profiles of 92 inflammatory proteins were measured in the blood of psoriasis patients both before and after treatment with tofacitanib or etanercept. These proteomic profiles were used to develop statistical classifiers for predicting PASI75 responses to tofacitinib and etancercept

Organism:

Homo sapiens

Type:

Other

Platform:

GPL27152

528 Samples

Download data: XLSX

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.

Organism:

Homo sapiens

Type:

Other

Platforms:

GPL27152 GPL27151

1020 Samples

Download data

(Submitter supplied) Proteomic profiles of 91 cardiovascular disease proteins were measured in the blood of psoriasis patients both before and after treatment with tofacitanib or etanercept. These proteomic profiles were used to develop statistical classifiers for predicting PASI75 responses to tofacitinib and etancercept

Organism:

Homo sapiens

Type:

Other

Platform:

GPL27151

492 Samples

Download data: XLSX

(Submitter supplied) Tofacitinib is an oral Janus kinase inhibitor being investigated for psoriasis. We sought to elucidate the molecular mechanisms underlying the clinical efficacy of tofacitinib in patients with psoriasis. Twelve patients with plaque psoriasis were randomized (3:1) to receive 10 mg of tofacitinib or placebo twice daily for 12 weeks. Biopsy specimens were taken from nonlesional (baseline) and lesional (baseline, days 1 and 3, and weeks 1, 2, 4, and 12) skin. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL570

95 Samples

Download data: CEL

(Submitter supplied) Prediction of response to adalimumab and methotrexate treatments based on gene expression profiles at baseline, weeks 1, 2, 4 and 16

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL10558

179 Samples

Download data: TXT

(Submitter supplied) Activation of Sirtuin (silent mating type information regulation 2 homolog) 1, or SIRT1, is an unexplored therapeutic approach for treatment of inflammatory diseases. The goal of this study was to evaluate the clinical activity and tolerability of multiple doses of SRT2104, a selective activator of SIRT1, in patients with moderate to severe psoriasis after day 84 of treatment. Forty patients were randomized 4:1 to three escalating doses of SRT2104 (250, 500, 1000 mg/d SRT2104 or placebo). more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL570

22 Samples

Download data: CEL

(Submitter supplied) A gene expression profiling sub-study was conducted in which skin biopsy samples were collected from 85 patients with moderate-to-severe psoriasis who were participating in ACCEPT, an IRB-approved Phase 3, multicenter, randomized trial. This analysis identified 4,175 probe-sets as being significantly modulated in psoriasis lesions (LS) compared with matched biopsies of non-lesional (NL) skin.

Organism:

Homo sapiens

Type:

Expression profiling by array

Dataset:

GDS4600

Platform:

GPL570

170 Samples

Download data: CEL

(Submitter supplied) The success of TNF inhibitors for treatment of psoriasis and other inflammatory diseases was previously attributed to blockade of innate immunity. In a clinical trial using etanercept TNF blocking agent to treat psoriasis vulgaris, we used affymetrix gene arrays to analyze broad gene profiles in lesional skin at multiple timepoints during drug treatment (baseline, and weeks 1, 2, 4 and 12) compared to non-lesional skin. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL571

89 Samples

Download data: CEL

Analysis of 85 paired lesional and non-lesional samples from moderate-to-severe psoriasis patients at baseline without active psoriasis therapy. Results provide insight into the molecular mechanisms underlying psoriasis.

Organism:

Homo sapiens

Type:

Expression profiling by array, transformed count, 2 disease state, 33 individual, 82 other, 10 specimen sets

Platform:

GPL570

Series:

GSE30999

170 Samples

Download data: CEL